@Arizona agree. More "soft" news. I don't think BVN should have marked this announcement price sensitive.

There are hundreds of probiotic strains in the market, and many thousands of potential strains for known bacteria species used in probiotics.

All it means is that they have the IP for this strain, Now we have to see if it has any positive health effects. The clincal studies in probiotics are relatively quick, have to pass a low bar, tend to be published in lower impact journals, and with shorter registration hurdles/times. There are several "proven" strains in the L. plantarum species, so having the IP for this isolated strain makes it a candidate for several potential studies.

So, it provides some evidence that they are continuing to drive the product development pipeline.

But price sensitive,... no way.

Fortunately, the market is behaving rationally on this one, today.

I think BVN needs to be careful not to lose credibility when making these announcements.